In the present study, activation of Chk1 is followed by inhibitory phosphorylation of CDK1 and it has been reported that pharmacologic and genetic inhibition of CDK137 or knock-down of upstream CDC25A38 induces differentiation through C/EBPα in AML cells with activated FLT3. This evidence concerns the gene CDK1 and acute myeloid leukemia.